NASDAQ:IMVT Immunovant - IMVT Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Immunovant, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $18.29 +0.09 (+0.49%) (As of 02/2/2023 12:00 AM ET) Add Compare Share Share Today's Range$17.70▼$18.5050-Day Range$12.70▼$19.7252-Week Range$3.14▼$20.24Volume1.03 million shsAverage Volume1.31 million shsMarket Capitalization$2.36 billionP/E RatioN/ADividend YieldN/APrice Target$16.86 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Immunovant MarketRank™ ForecastAnalyst RatingModerate Buy2.80 Rating ScoreUpside/Downside7.8% Downside$16.86 Price TargetShort InterestHealthy4.68% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.62Based on 5 Articles This WeekInsider TradingSelling Shares$1.35 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($1.56) to ($1.60) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.40 out of 5 starsMedical Sector963rd out of 1,030 stocksBiological Products, Except Diagnostic Industry158th out of 169 stocks 1.4 Analyst's Opinion Consensus RatingImmunovant has received a consensus rating of Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $16.86, Immunovant has a forecasted downside of 7.8% from its current price of $18.29.Amount of Analyst CoverageImmunovant has only been the subject of 3 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted4.68% of the float of Immunovant has been sold short.Short Interest Ratio / Days to CoverImmunovant has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Immunovant has recently decreased by 32.50%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldImmunovant does not currently pay a dividend.Dividend GrowthImmunovant does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IMVT. Previous Next 2.6 News and Social Media Coverage News SentimentImmunovant has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.40 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Immunovant this week, compared to 2 articles on an average week.Search InterestOnly 21 people have searched for IMVT on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Immunovant to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Immunovant insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,346,710.00 in company stock.Percentage Held by InsidersOnly 3.00% of the stock of Immunovant is held by insiders.Percentage Held by InstitutionsOnly 32.77% of the stock of Immunovant is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Immunovant are expected to decrease in the coming year, from ($1.56) to ($1.60) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Immunovant is -11.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Immunovant is -11.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImmunovant has a P/B Ratio of 4.53. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Immunovant (NASDAQ:IMVT) StockImmunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.Read More Receive IMVT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immunovant and its competitors with MarketBeat's FREE daily newsletter. Email Address IMVT Stock News HeadlinesJanuary 28, 2023 | americanbankingnews.comImmunovant, Inc. (NASDAQ:IMVT) Insider Mark S. Levine Sells 10,156 SharesDecember 29, 2022 | finance.yahoo.comWe Think Immunovant (NASDAQ:IMVT) Can Afford To Drive Business GrowthFebruary 3, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.December 16, 2022 | finance.yahoo.com4 Drug Stocks Up More Than 40% YTD With Room to Grow in 2023December 15, 2022 | finance.yahoo.comAre Medical Stocks Lagging Immunovant (IMVT) This Year?November 8, 2022 | finance.yahoo.comImmunovant's (IMVT) Q2 Earnings In Line, Batoclimab in FocusNovember 7, 2022 | finance.yahoo.comImmunovant to Present at Guggenheim 4th Annual Immunology and Neurology Day on November 14thNovember 4, 2022 | finance.yahoo.comImmunovant Reports Financial Results and Recent Business Updates for the Quarter Ended September 30, 2022February 3, 2023 | Tradewins (Ad)Know Your Profit Potential BEFORE You Trade!I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! October 20, 2022 | finance.yahoo.comImmunovant (IMVT) Set to Develop Lead Candidate BatoclimabOctober 9, 2022 | finance.yahoo.comWhile institutions invested in Immunovant, Inc. (NASDAQ:IMVT) benefited from last week's 63% gain, public companies stood to gain the mostOctober 7, 2022 | nasdaq.comThese Biotech Stocks Hit New 52-week High, Were They In Your Portfolio? - NasdaqOctober 6, 2022 | nasdaq.comHealth Care Sector Update for 10/04/2022: GBS, IMVT, KALV - NasdaqOctober 6, 2022 | fool.comWhy Immunovant Stock Is Skyrocketing This Week - The Motley FoolOctober 6, 2022 | finance.yahoo.comWhy Immunovant Stock Is Skyrocketing This WeekOctober 6, 2022 | uk.investing.comWhy Nauticus Robotics Shares Are Trading Higher By 96%; Here Are 67 Biggest Movers From Yesterday By Benzinga - Investing.com UKOctober 5, 2022 | benzinga.comWhy Sotera Health Shares Are Trading Lower By Around 13%, Here Are 38 Stocks Moving In Wednesday's Mid-Da - BenzingaOctober 5, 2022 | streetinsider.comR&D Efforts to Improve Optimal Treatments for Advanced Pancreatic Ductal Adenocarcinoma (PDAC) Progressing - StreetInsider.comOctober 5, 2022 | uk.investing.comRPM International, Lamb Weston And Some Other Big Stocks Moving Higher On Wednesday By Benzinga - Investing.com UKOctober 5, 2022 | marketwatch.comImmunovant Shares Rise 32% After $75M Stock Offering Prices - MarketWatchOctober 5, 2022 | benzinga.comNasdaq Surges 250 Points; Crude Oil Rises Sharply - FaZe Holdings (NASDAQ:FAZE), AeroClean Technologies ( - BenzingaOctober 5, 2022 | finance.yahoo.comHanAll's Second FcRn Inhibitor HL161ANS to be Added to the Development Program of its Licensed Partner - Yahoo FinanceOctober 4, 2022 | benzinga.comNasdaq Surges 350 Points; Crude Oil Rises Sharply - FaZe Holdings (NASDAQ:FAZE), AeroClean Technologies ( - BenzingaOctober 4, 2022 | benzinga.comHanAll's Second FcRn Inhibitor HL161ANS to be Added to the Development Program of its Licensed Partner - BenzingaOctober 4, 2022 | benzinga.comImmunovant shares are trading lower after the company announced pricing of a $75 million underwritten offering of common stock. - Immunovant (NASDAQ:IMVT) - BenzingaOctober 4, 2022 | seekingalpha.comInhibrx, Immunovant top healthcare gainers; Biohaven, KalVista lead losers' pack - Seeking AlphaOctober 4, 2022 | globenewswire.comImmunovant Announces Pricing of $75.0 Million Underwritten Offering of Common Stock - GlobeNewswireSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive IMVT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immunovant and its competitors with MarketBeat's FREE daily newsletter. Email Address IMVT Company Calendar Last Earnings11/05/2021Today2/03/2023Next Earnings (Estimated)2/03/2023Fiscal Year End3/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:IMVT CUSIPN/A CIK1764013 Webwww.immunovant.com PhoneN/AFaxN/AEmployees68Year FoundedN/APrice Target and Rating Average Stock Price Forecast$16.86 High Stock Price Forecast$30.00 Low Stock Price Forecast$5.00 Forecasted Upside/Downside-7.8%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.53) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-156,730,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-39.15% Return on Assets-36.36% Debt Debt-to-Equity RatioN/A Current Ratio13.41 Quick Ratio13.41 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.04 per share Price / Book4.53Miscellaneous Outstanding Shares129,180,000Free Float125,307,000Market Cap$2.36 billion OptionableNot Optionable Beta1.00 Key ExecutivesDr. Frank M. Torti M.B.A. (Age 44)M.D., MBA, Exec. Chairperson of the Board Comp: $94.11kDr. Peter Salzmann M.B.A. (Age 55)M.D., CEO & Director Comp: $979.96kMs. Eva Renee Barnett M.B.A. (Age 43)Chief Financial Officer Comp: $534.98kDr. William L. Macias M.D. (Age 65)Ph.D., Chief Medical Officer Comp: $4.85MDr. Julia G. Butchko Ph.D. (Age 52)Chief Devel. & Technology Officer Dr. Chau Cheng M.B.A.Ph.D., VP of Investor RelationsMr. Mark S. Levine (Age 50)Chief Legal Officer & Corp. Sec. Ms. Lauren Schrier M.B.A.VP of MarketingMore ExecutivesKey CompetitorsRevolution MedicinesNASDAQ:RVMDKrystal BiotechNASDAQ:KRYSRelay TherapeuticsNASDAQ:RLAYKymera TherapeuticsNASDAQ:KYMRSpringWorks TherapeuticsNASDAQ:SWTXView All CompetitorsInsiders & InstitutionsConcorde Asset Management LLCBought 16,725 shares on 2/2/2023Ownership: 0.013%ProShare Advisors LLCBought 2,186 shares on 2/2/2023Ownership: 0.013%Bailard Inc.Bought 12,200 shares on 2/2/2023Ownership: 0.009%Simplex Trading LLCSold 10,000 shares on 2/2/2023Ownership: 0.000%Zurcher Kantonalbank Zurich Cantonalbank Sold 784 shares on 2/1/2023Ownership: 0.006%View All Insider TransactionsView All Institutional Transactions IMVT Stock - Frequently Asked Questions Should I buy or sell Immunovant stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Immunovant in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" IMVT shares. View IMVT analyst ratings or view top-rated stocks. What is Immunovant's stock price forecast for 2023? 5 Wall Street analysts have issued 1 year price objectives for Immunovant's stock. Their IMVT share price forecasts range from $5.00 to $30.00. On average, they anticipate the company's share price to reach $16.86 in the next twelve months. This suggests that the stock has a possible downside of 7.8%. View analysts price targets for IMVT or view top-rated stocks among Wall Street analysts. How have IMVT shares performed in 2023? Immunovant's stock was trading at $17.75 at the beginning of the year. Since then, IMVT stock has increased by 3.0% and is now trading at $18.29. View the best growth stocks for 2023 here. Are investors shorting Immunovant? Immunovant saw a decline in short interest in the month of January. As of January 15th, there was short interest totaling 2,430,000 shares, a decline of 32.5% from the December 31st total of 3,600,000 shares. Based on an average daily volume of 1,170,000 shares, the short-interest ratio is presently 2.1 days. Approximately 4.7% of the shares of the company are sold short. View Immunovant's Short Interest. When is Immunovant's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, February 3rd 2023. View our IMVT earnings forecast. How were Immunovant's earnings last quarter? Immunovant, Inc. (NASDAQ:IMVT) announced its quarterly earnings results on Friday, November, 4th. The company reported ($0.41) EPS for the quarter, hitting the consensus estimate of ($0.41). What other stocks do shareholders of Immunovant own? Based on aggregate information from My MarketBeat watchlists, some companies that other Immunovant investors own include Salesforce (CRM), NVIDIA (NVDA), Advanced Micro Devices (AMD), Walt Disney (DIS), Fulcrum Therapeutics (FULC), Myovant Sciences (MYOV), Alibaba Group (BABA), Inovio Pharmaceuticals (INO), JD.com (JD) and Johnson & Johnson (JNJ). What is Immunovant's stock symbol? Immunovant trades on the NASDAQ under the ticker symbol "IMVT." Who are Immunovant's major shareholders? Immunovant's stock is owned by many different institutional and retail investors. Top institutional shareholders include Hennion & Walsh Asset Management Inc. (0.20%), Sigma Planning Corp (0.04%), Strs Ohio (0.03%), Concorde Asset Management LLC (0.01%), ProShare Advisors LLC (0.01%) and Allspring Global Investments Holdings LLC (0.01%). Insiders that own company stock include Atul Pande, Douglas J Hughes, Eva Renee Barnett, Frank Torti, George V Migausky, Julia G Butchko, Mark S Levine, Peter Salzmann, Sciences Ltd Roivant and William L Macias. View institutional ownership trends. How do I buy shares of Immunovant? Shares of IMVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Immunovant's stock price today? One share of IMVT stock can currently be purchased for approximately $18.29. How much money does Immunovant make? Immunovant (NASDAQ:IMVT) has a market capitalization of $2.36 billion. The company earns $-156,730,000.00 in net income (profit) each year or ($1.53) on an earnings per share basis. How can I contact Immunovant? Immunovant's mailing address is 320 WEST 37TH STREET, NEW YORK NY, 10018. The official website for the company is www.immunovant.com. The company can be reached via email at info@immunovant.com. This page (NASDAQ:IMVT) was last updated on 2/3/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.